StockData
Jaguar Health, Inc. logo

Jaguar Health, Inc. (JAGX) shareholders

JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.39−0.03 (-7.14%)

Close on Nov 16, 2026Market cap $2.02MP/E –Yield –

Ownership

Who owns Jaguar Health's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
John Fife and Fredrick Waid1,290,0009.90%13G (passive)Jan 29, 2025
Iliad Management, LLC
Joint filing with Iliad Research & Trading, L.P. (9.80%), Fife Trading, Inc. (9.80%) and 1 more
440,0009.80%13G (passive)Dec 11, 2025
Joshua Mailman189,6179.99%13G (passive) amendmentSep 12, 2026
Heights Capital Management, Inc.
Joint filing with CVI Investments, Inc. (9.90%)
103,9129.90%13G (passive)May 20, 2025

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lisa A. ConteSee Remarks, Director29,2580.57%Jan 21, 2026
Jonathan S. WolinSee Remarks11,9380.23%Jan 21, 2026
Steven R. KingSee Remarks11,8850.23%Jan 21, 2026
Carol R. LizakChief Financial Officer11,9120.23%Dec 15, 2025
Pravin R. ChaturvediChief Scientific Officer11,9380.23%Dec 15, 2025
John MicekDirector7,4300.14%Mar 12, 2026
Anula JayasuriyaDirector5,9160.11%Dec 15, 2025
James J. BochnowskiDirector188,0333.64%Dec 15, 2025
Jonathan B. SiegelDirector7,4820.14%Dec 15, 2025
Alternative Strategies LLC Lincoln10% owner600,00011.61%Aug 29, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
John Micek
Director
Dec 11, 2025Award+7,377––7,430
Steven R. King
See Remarks
Dec 11, 2025Award+11,740––11,885
Jonathan S. Wolin
See Remarks
Dec 11, 2025Award+11,740––11,938
Lisa A. Conte
See Remarks, Director
Dec 11, 2025Award+28,592––29,258
Carol R. Lizak
Chief Financial Officer
Dec 11, 2025Award+11,740––11,911
Jonathan B. Siegel
Director
Dec 11, 2025Award+7,377––7,423
James J. Bochnowski
Director
Dec 11, 2025Award+6,363––6,415
Anula Jayasuriya
Director
Dec 11, 2025Award+5,870––5,916
Pravin R. Chaturvedi
Chief Scientific Officer
Dec 11, 2025Award+11,740––11,938
Lisa A. Conte
CEO and President, Director
May 17, 2025Option exercise+2––666
Steven R. King
See Remarks
May 17, 2025Option exercise+1––145
Steven R. King
See Remarks
Oct 8, 2024Award+4,922––4,951
Jonathan S. Wolin
See Remarks
Oct 8, 2024Award+4,922––4,955
Lisa A. Conte
See Remarks, Director
Oct 8, 2024Award+16,503––16,624
Pravin R. Chaturvedi
Chief Scientific Officer
Oct 8, 2024Award+4,922––4,957
Carol R. Lizak
Chief Financial Officer
Oct 8, 2024Award+4,280––4,297
Lisa A. Conte
CEO and President, Director
May 17, 2024Option exercise+2,695––7,295
Carol R. Lizak
Chief Financial Officer
May 17, 2024Option exercise+431––1,042
Pravin R. Chaturvedi
Chief Scientific Officer
May 17, 2024Option exercise+871––2,141
Jonathan S. Wolin
Chief of Staff, CCO & GC
May 17, 2024Option exercise+871––2,012
Steven R. King
See Remarks
May 17, 2024Option exercise+612––1,756
Lisa A. Conte
CEO and President, Director
Apr 5, 2024Option exercise+600––4,600
Jonathan S. Wolin
Chief of Staff, CCO & GC
Apr 5, 2024Option exercise+89––1,141
Carol R. Lizak
Chief Financial Officer
Apr 5, 2024Option exercise+60––611
Steven R. King
See Remarks
Apr 5, 2024Option exercise+178––1,144
Pravin R. Chaturvedi
Chief Scientific Officer
Apr 5, 2024Option exercise+134––1,270
Steven R. King
see remarks
Aug 14, 2023Award+159,168––160,133
Carol R. Lizak
Chief Financial Officer
Aug 14, 2023Award+142,088––142,745
Anula Jayasuriya
Director
Aug 14, 2023Award+68,568––70,286
Jonathan S. Wolin
Chief of Staff, CCO & GC
Aug 14, 2023Award+196,628––197,680
James J. Bochnowski
Director
Aug 14, 2023Award+76,613––78,876
Lisa A. Conte
CEO and President, Director
Aug 14, 2023Award+383,605––387,605
John Micek
Director
Aug 14, 2023Award+68,568––80,701
Pravin R. Chaturvedi
Chief Scientific Officer
Aug 14, 2023Award+204,192––205,328
Jonathan B. Siegel
Director
Aug 14, 2023Award+68,568––69,874
Anula Jayasuriya
Director
Jul 1, 2023Award+1,718––1,718
Carol R. Lizak
Chief Financial Officer
May 17, 2023Option exercise+431––657
James J. Bochnowski
Director
May 17, 2023Option exercise+1,280––2,263
Steven R. King
Chief of Sustainable Supply
May 17, 2023Option exercise+611––965
Jonathan B. Siegel
Director
May 17, 2023Option exercise+1,145––1,306
Lisa A. Conte
CEO and President, Director
May 17, 2023Option exercise+2,694––4,000
Pravin R. Chaturvedi
Chief Scientific Officer
May 17, 2023Option exercise+870––1,136
John Micek
Director
May 17, 2023Option exercise+1,145––1,306
Jonathan S. Wolin
Chief of Staff, CCO & GC
May 17, 2023Option exercise+871––1,052
Pravin R. Chaturvedi
Chief Scientific Officer
Apr 5, 2023Option exercise+133––266
Lisa A. Conte
CEO and President, Director
Apr 5, 2023Option exercise+600––1,306
Carol R. Lizak
Chief Financial Officer
Apr 5, 2023Option exercise+60––226
Jonathan S. Wolin
Chief of Staff, CCO & GC
Apr 5, 2023Option exercise+88––181
Pravin R. Chaturvedi
Chief Scientific Officer
Apr 5, 2023Option exercise+44––88
Steven R. King
Chief of Sustainable Supply
Apr 5, 2023Option exercise+177––354
Jonathan S. Wolin
Chief of Staff, CCO & GC
Dec 31, 2022Buy+317$0.03$106,983
Gregory J. Divis
Director
May 18, 2022Option exercise+12,133––12,133
John Micek
Director
May 18, 2022Option exercise+12,133––12,133
James J. Bochnowski
Director
May 18, 2022Option exercise+13,133––73,765
Jonathan B. Siegel
Director
May 18, 2022Option exercise+12,133––12,133
Pravin R. Chaturvedi
Chief Scientific Officer
Apr 5, 2022Option exercise+10,000––10,000
Carol R. Lizak
Chief Financial Officer
Apr 5, 2022Option exercise+4,513––12,481
Lisa A. Conte
CEO and President, Director
Apr 5, 2022Option exercise+45,000––53,003
Pravin R. Chaturvedi
Chief Scientific Officer
Apr 5, 2022Option exercise+3,333––3,333
Jonathan S. Wolin
Chief of Staff, CCO & GC
Apr 5, 2022Option exercise+6,666––6,666

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.69%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
+42.8%
From 0M shares
Short volume, 20 days
40.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jaguar Health's stock actually held short. Settlement fails (shares not delivered on time) peaked at 129,472 shares on Oct 8, 2026 over the last 90 days.

See a number that looks wrong?